Cancer methods
AssigneeImperial Innovations Limited
InventorHani Gabra
Life of this patent
Estimating the term…
Abstract
A method of treating a patient having a cancer in which HER2, HER4, FGFR1, EPHA2 and/or FGFR3 is upregulated and/or in which HER2, HER4, FGFR1, EPHA2 and/or FGFR3 mediated-signaling is upregulated, the method comprising administering to the patient a compound comprising or consisting of an OPCML polypeptide (SEQ ID NO: 1), or a fragment thereof which comprises at least one Ig domain of OPCML, or a variant thereof having at least 90% sequence identity with the OPCML polypeptide or the fragment thereof, or a nucleic acid molecule which encodes the OPCML polypeptide or fragment or variant thereof.
Claims37
A method of treating a patient having a cancer in which HER2, HER4, FGFR1, EPHA2 and/or FGFR3 is upregulated and/or in which HER2, HER4, FGFR1, EPHA2 and/or FGFR3 mediated-signaling is upregulated, the method comprising administering to the patient a compound comprising or consisting of an OPCML polypeptide (SEQ ID NO:
- 1), or a fragment thereof which comprises at least one Ig domain of OPCML, or a variant thereof having at least 90% sequence identity with the OPCML polypeptide or the fragment thereof, or a nucleic acid molecule which encodes the OPCML polypeptide or fragment or variant thereof.
-5. (canceled)
-14. (canceled)
A method according to claim 14 wherein the cancer is ovarian cancer.
-192. (canceled)
(canceled)
A pharmaceutical composition comprising a fragment of OPCML, preferably human OPCML, that lacks the GPI-anchor site, and a pharmaceutically acceptable carrier, diluent or excipient.
(canceled)
A method of treating cancer, the method comprising administering a fragment of OPCML, preferably human OPCML, that lacks the GPI-anchor site, to a patient in need thereof.
199-200. (canceled)
Dependencies are inferred from the claim text.